GB201322456D0 - Radiotracer compositions and methods - Google Patents

Radiotracer compositions and methods

Info

Publication number
GB201322456D0
GB201322456D0 GBGB1322456.3A GB201322456A GB201322456D0 GB 201322456 D0 GB201322456 D0 GB 201322456D0 GB 201322456 A GB201322456 A GB 201322456A GB 201322456 D0 GB201322456 D0 GB 201322456D0
Authority
GB
United Kingdom
Prior art keywords
methods
radiotracer
compositions
radiotracer compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1322456.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Priority to GBGB1322456.3A priority Critical patent/GB201322456D0/en
Publication of GB201322456D0 publication Critical patent/GB201322456D0/en
Priority to EP14814895.0A priority patent/EP3082879A1/en
Priority to US15/102,952 priority patent/US10300156B2/en
Priority to PCT/EP2014/078609 priority patent/WO2015091882A1/en
Priority to JP2016539089A priority patent/JP6824738B2/ja
Priority to CN201480069324.9A priority patent/CN105848687B/zh
Priority to US16/375,223 priority patent/US11311636B2/en
Priority to JP2019124883A priority patent/JP2019206533A/ja
Priority to US17/695,810 priority patent/US20220202965A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
GBGB1322456.3A 2013-12-18 2013-12-18 Radiotracer compositions and methods Ceased GB201322456D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1322456.3A GB201322456D0 (en) 2013-12-18 2013-12-18 Radiotracer compositions and methods
EP14814895.0A EP3082879A1 (en) 2013-12-18 2014-12-18 Radiotracer compositions and methods
US15/102,952 US10300156B2 (en) 2013-12-18 2014-12-18 Radiotracer compositions and methods
PCT/EP2014/078609 WO2015091882A1 (en) 2013-12-18 2014-12-18 Radiotracer compositions and methods
JP2016539089A JP6824738B2 (ja) 2013-12-18 2014-12-18 放射性トレーサー組成物及び方法
CN201480069324.9A CN105848687B (zh) 2013-12-18 2014-12-18 放射性示踪剂组合物和方法
US16/375,223 US11311636B2 (en) 2013-12-18 2019-04-04 Radiotracer compositions and methods
JP2019124883A JP2019206533A (ja) 2013-12-18 2019-07-04 放射性トレーサー組成物及び方法
US17/695,810 US20220202965A1 (en) 2013-12-18 2022-03-15 Radiotracer compositions and methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1322456.3A GB201322456D0 (en) 2013-12-18 2013-12-18 Radiotracer compositions and methods

Publications (1)

Publication Number Publication Date
GB201322456D0 true GB201322456D0 (en) 2014-02-05

Family

ID=50071052

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1322456.3A Ceased GB201322456D0 (en) 2013-12-18 2013-12-18 Radiotracer compositions and methods

Country Status (6)

Country Link
US (3) US10300156B2 (https=)
EP (1) EP3082879A1 (https=)
JP (2) JP6824738B2 (https=)
CN (1) CN105848687B (https=)
GB (1) GB201322456D0 (https=)
WO (1) WO2015091882A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN108218651B (zh) * 2018-02-27 2023-11-03 首都医科大学宣武医院 用于制备放射性药物的一次性辅助装置及方法
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction
GB201915206D0 (en) * 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
GB201919016D0 (en) * 2019-12-20 2020-02-05 Ge Healthcare Ltd Apparatus and method for solid phase extraction
EP4087592A1 (en) * 2020-01-10 2022-11-16 Real Isolates, LLC Methods for obtaining compounds from a plant or fungus material, respective compositions, and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
GB0105224D0 (en) 2001-03-02 2001-04-18 Nycomed Amersham Plc Improved peptide-chelate conjugates
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
EP1516185A4 (en) 2001-12-27 2007-06-20 Van Andel Res Inst Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US7018614B2 (en) 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
JP2006505610A (ja) * 2002-11-05 2006-02-16 イヨン ベアム アプリカスィヨン エッス．アー． １８−ｆ標識放射性製剤の安定化
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
EP1952826A4 (en) 2005-10-24 2011-05-18 Fujifilm Ri Pharma Co Ltd DIAGNOSTIC AGENT AND THERAPEUTIC AGENT FOR DISEASES RELATED TO THE HEPATOCYTE GROWTH FACTOR RECEPTOR
US20100068150A1 (en) 2006-07-07 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Selective Caspase Inhibitors
GB0615211D0 (en) 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
US8247534B2 (en) 2006-12-13 2012-08-21 Ge Healthcare As Synthesis of radiofluorinated peptide using microwave activation technology
JP2010520229A (ja) 2007-03-01 2010-06-10 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 放射性弗素化方法
ATE551073T1 (de) 2007-05-16 2012-04-15 Ge Healthcare As Markierte hgf-bindende peptide für bildgebung
GB0718957D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
JP5399422B2 (ja) * 2008-02-28 2014-01-29 ジーイー・ヘルスケア・リミテッド 市販の安価な化学薬品からのｐｅｇ−６成分の合成
US8435454B2 (en) * 2009-07-09 2013-05-07 Siemens Medical Solutions Usa, Inc. Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
GB201020314D0 (en) 2010-12-01 2011-01-12 Ge Healthcare Ltd Apoptosis pet imaging agents
CA2819347A1 (en) 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method
CN107753962A (zh) 2010-12-09 2018-03-06 通用电气健康护理有限公司 放射性示踪剂组合物
CN103370084B (zh) * 2010-12-21 2016-11-09 通用电气健康护理有限公司 苯胺在肟连接的放射稳定化中的应用
RU2013128360A (ru) 2010-12-22 2015-01-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Her2-связывающие белки, меченые 18f-содержащим кремнийорганическим соединением
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
GB201202420D0 (en) * 2012-02-13 2012-03-28 Ge Healthcare Ltd Radiotracer compositions
GB201209082D0 (en) * 2012-05-24 2012-07-04 Ge Healthcare Ltd Purification method
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322451D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods

Also Published As

Publication number Publication date
US20190275182A1 (en) 2019-09-12
EP3082879A1 (en) 2016-10-26
US20220202965A1 (en) 2022-06-30
US10300156B2 (en) 2019-05-28
JP6824738B2 (ja) 2021-02-03
CN105848687B (zh) 2020-06-09
US20160303263A1 (en) 2016-10-20
US11311636B2 (en) 2022-04-26
JP2019206533A (ja) 2019-12-05
CN105848687A (zh) 2016-08-10
WO2015091882A1 (en) 2015-06-25
JP2017502946A (ja) 2017-01-26

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
GB2521022B (en) Compositions and methods
IL286759A (en) Therapeutic methods and preparations
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
GB201308072D0 (en) Compositions and methods
IL244850B (en) Stabilized epinaconazole preparations, and their uses
IL241225A0 (en) Plant-based compositions and their uses
IL265876A (en) Preparations that include 15-ohepa and methods of using them
GB201317286D0 (en) Composition and Use
SG11201509136YA (en) Cenicriviroc compositions and methods of making and using the same
GB201321693D0 (en) Composition and uses thereof
SG11201509448WA (en) Creamer compositions and uses thereof
GB201305414D0 (en) Method and composition
GB201305813D0 (en) Compositions and methods
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
GB201322456D0 (en) Radiotracer compositions and methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
SG11201604904XA (en) Detergent and rinse-aid compositions and methods
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
GB201308242D0 (en) Compositions and uses thereof
EP3003323A4 (en) POLYSACCARIDE COMPOSITIONS AND CORRESPONDING METHODS
GB201301022D0 (en) Composition and uses thereof
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
GB201319255D0 (en) Therapeutic compositions and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)